COMMUNIQUÉS West-GlobeNewswire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
21/11/2025
SAN CARLOS, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
21/11/2025
TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of [...]
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
21/11/2025
-- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved [...]
Brain Injury Association of America Honored Centre for Neuro Skills’ Dr. Mark Ashley as Luminary of the Year
21/11/2025
BAKERSFIELD, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- The Brain Injury Association of America (BIAA) honored Dr. Mark J. Ashley, Founder and Executive Chairman of the Board of Centre for Neuro Skills (CNS), as Luminary [...]
TrialWire’s™ Industry Leading AI-powered Patient Recruitment Platform Delivers Continuous Clinical Trial Referrals over Holiday Season
21/11/2025
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- TrialWire ™, the industry’s fastest, advanced AI-powered, algorithm-driven patient recruitment platform, today announced its RapidStart™ and RapidRescue™ solutions are [...]
Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.
21/11/2025
PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
Inventiva publie ses informations financières du 3ème trimestre 2025¹
21/11/2025
Trésorerie et équivalents de trésorerie à 97,6 millions d’euros, et 24,7 millions d’euros en dépôts à court terme 2 au 30 septembre. Chiffre d’affaires de 4,5 millions d’euros sur les neuf premiers mois de 2025. Horizon [...]
Inventiva reports 2025 Third Quarter Financial Information¹
21/11/2025
Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits 2 as of September 30, 2025. Revenues of €4.5 million for the first nine months of 2025. Cash runway expected until the end of the [...]
Echo IQ to Participate in the Piper Sandler 37th Annual Healthcare Conference
21/11/2025
SYDNEY, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ), today announced that Dustin Haines, Chief Executive Officer, will participate in a fireside [...]
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
21/11/2025
ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
21/11/2025
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21/11/2025
NOVATO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
21/11/2025
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
21/11/2025
PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+ NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. ( TSXV: [...]
Actimed Therapeutics Announces Important Licensing Agreement with Mankind Pharma
21/11/2025
Covers exclusive rights to S-pindolol, the novel therapy in development for the treatment of cachexia, in India and South Asia Represents a major step in the mission of Actimed to bring the first globally approved [...]
Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025
21/11/2025
WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”) , a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
21/11/2025
EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding [...]
Adlai Nortye to Participate in Upcoming Investor Conferences
21/11/2025
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
21/11/2025
90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatment Study will run approximately 12 months and enroll up to 100 patients Internal estimates of the [...]

Pages